Bioaffinity Technologies Inc (BIAF) Stock Price, Quote & News

Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indica...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 210 698 5334

Website: bioaffinitytech.com

Address:

3300 Nacogdoches Road, Suite 216, San Antonio, United States

Emiclea May. 12 at 10:38 PM

$BIAF This is going to Run!!!

1 · Reply

Emiclea May. 12 at 8:33 PM

$BIAF load up on this . . I telling you this is a steal under $2

1 · Reply

Prettyricky13 May. 12 at 4:39 PM

$BIAF dam don’t look good the news didn’t help I keep watching

0 · Reply

GraceUnderPressure2112 May. 12 at 2:25 PM

$BIAF down she goes...

0 · Reply

TMacIE May. 12 at 2:18 PM

$BIAF

0 · Reply

Emiclea May. 12 at 1:28 PM

$BIAF let’s go !! Run it !!

0 · Reply

Stock_Catcher May. 12 at 1:15 PM

$BIAF bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

1 · Reply

focafoca99 May. 8 at 12:48 PM

$BIAF released its Q1 2026 financial results via a press release attached to its 8‑K.

0 · Reply

PyroMatic May. 5 at 4:21 AM

$BIAF On April 28, 2026, the company launched a new study with Brooke Army Medical Center. They are testing if their CyPath® Lung technology can identify inflammatory biomarkers in asthma and COPD patients. This targets a massive airway disease treatment market estimated at $92 billion.

1 · Reply

BiotechGoldenEra May. 5 at 2:27 AM

$BIAF bottom?

0 · Reply

BioAffinity says CyPath Lung test unit sales achieved monthly record in April

May 12, 2026, 9:15 AM EDT - 23 hours ago

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

2026-05-08T17:10:03.000Z - 4 days ago

BioAffinity Technologies reports Q1 EPS (81c) vs. ($4.80) last year

May 8, 2026, 8:30 AM EDT - 5 days ago

bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung

2026-04-30T21:19:40.000Z - 12 days ago

BioAffinity Technologies files to sell 497,483 shares of common stock for holder

2026-04-28T14:04:05.000Z - 14 days ago

BioAffinity Technologies launches new study to expand use of CyPath lung tech

Apr 28, 2026, 9:16 AM EDT - 14 days ago

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

2026-04-14T12:05:28.000Z - 4 weeks ago

BioAffinity Technologies releases clinical case on CyPath Lung

Apr 14, 2026, 8:00 AM EDT - 4 weeks ago

New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

Apr 8, 2026, 7:00 PM EDT - 4 weeks ago

bioAffinity Technologies Transcript: Status update

2026-04-07T12:14:58.000Z - 5 weeks ago

BioAffinity announces CyPath Lung to be featured at Cleveland Clinic symposium

Apr 7, 2026, 8:00 AM EDT - 5 weeks ago

bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

2026-04-01T12:15:44.000Z - 6 weeks ago

BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1

Apr 1, 2026, 8:00 AM EDT - 6 weeks ago

bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

Mar 25, 2026, 8:00 AM EDT - 7 weeks ago

bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

Mar 17, 2026, 7:45 AM EDT - 2 months ago

New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

Mar 13, 2026, 8:00 AM EDT - 2 months ago

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

2026-03-10T11:55:56.000Z - 2 months ago

BioAffinity Technologies initiates clinical study for CyPath Lung

Mar 10, 2026, 7:47 AM EDT - 2 months ago

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

Mar 3, 2026, 8:30 AM EST - 2 months ago

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

2026-02-25T14:26:54.000Z - 2 months ago

BioAffinity announces study to expand CyPath Lung sample collection options

Feb 25, 2026, 8:30 AM EST - 2 months ago

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

2026-02-19T16:05:20.000Z - 2 months ago

BioAffinity Technologies releases clinical case study on CyPath Lung test

Feb 19, 2026, 11:00 AM EST - 2 months ago

New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

Feb 17, 2026, 8:00 AM EST - 3 months ago

Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study

2026-02-09T13:37:21.000Z - 3 months ago

BioAffinity Technologies announces new appointments to Advisory Board

Feb 9, 2026, 8:00 AM EST - 3 months ago

bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

Jan 7, 2026, 8:00 AM EST - 4 months ago

bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

Dec 3, 2025, 8:00 AM EST - 5 months ago

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

Nov 14, 2025, 8:00 AM EST - 6 months ago

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 8:00 AM EST - 6 months ago

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

2025-10-28T13:05:39.000Z - 7 months ago

BioAffinity Technologies announces acceptance of Australian patent application

Oct 28, 2025, 8:00 AM EDT - 7 months ago

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

Oct 20, 2025, 8:00 AM EDT - 7 months ago

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

2025-10-16T12:11:21.000Z - 7 months ago

BioAffinity Technologies receives notification of allowance for algorithm patent

Oct 16, 2025, 8:00 AM EDT - 7 months ago

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

2025-10-15T12:10:54.000Z - 7 months ago

BioAffinity Technologies regains compliance with Nasdaq

Oct 15, 2025, 8:00 AM EDT - 7 months ago

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

Oct 9, 2025, 2:00 PM EDT - 7 months ago

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

2025-10-09T17:05:23.000Z - 7 months ago

BioAffinity Technologies announces closing of $1.8M registered direct offering

Oct 9, 2025, 1:00 PM EDT - 7 months ago

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 4:15 PM EDT - 7 months ago

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

2025-10-08T19:50:15.000Z - 7 months ago

BioAffinity Technologies announces $1.8M registered direct offering

Oct 8, 2025, 3:45 PM EDT - 7 months ago

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

2025-10-07T12:05:19.000Z - 7 months ago

BioAffinity Technologies reports record growth for CyPath Lung diagnostic test

Oct 7, 2025, 8:00 AM EDT - 7 months ago

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

Sep 30, 2025, 12:44 PM EDT - 8 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

Sep 30, 2025, 12:15 PM EDT - 8 months ago

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

Sep 29, 2025, 5:59 PM EDT - 8 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

2025-09-29T20:00:10.000Z - 8 months ago

BioAffinity prices 1.92M common share offering at $2.50 per share

Sep 29, 2025, 3:51 PM EDT - 8 months ago

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

2025-09-29T14:50:18.000Z - 8 months ago

bioAffinity Technologies Inc trading resumes

Sep 26, 2025, 8:00 AM EDT - 8 months ago

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

Sep 17, 2025, 8:15 AM EDT - 8 months ago

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Sep 9, 2025, 8:00 AM EDT - 8 months ago

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

Aug 18, 2025, 8:00 AM EDT - 9 months ago

bioAffinity Technologies Appoints New Members to Board of Directors

Aug 14, 2025, 4:15 PM EDT - 9 months ago

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 14, 2025, 8:00 AM EDT - 9 months ago

bioAffinity Technologies Reports Second Quarter 2025 Results

Aug 13, 2025, 9:25 AM EDT - 9 months ago

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 13, 2025, 8:00 AM EDT - 9 months ago

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Jul 29, 2025, 8:00 AM EDT - 10 months ago

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Jul 22, 2025, 9:00 AM EDT - 10 months ago

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

Jul 15, 2025, 9:00 AM EDT - 10 months ago

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

Jun 26, 2025, 9:00 AM EDT - 11 months ago

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

Jun 24, 2025, 9:00 AM EDT - 11 months ago

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

Jun 11, 2025, 9:00 AM EDT - 11 months ago

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

May 28, 2025, 9:00 AM EDT - 1 year ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 20, 2025, 9:00 AM EDT - 1 year ago

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 15, 2025, 8:30 AM EDT - 1 year ago

bioAffinity Technologies Reports First Quarter 2025 Results

May 8, 2025, 9:00 AM EDT - 1 year ago

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

Emiclea May. 12 at 10:38 PM

$BIAF This is going to Run!!!

1 · Reply

Emiclea May. 12 at 8:33 PM

$BIAF load up on this . . I telling you this is a steal under $2

1 · Reply

Prettyricky13 May. 12 at 4:39 PM

$BIAF dam don’t look good the news didn’t help I keep watching

0 · Reply

GraceUnderPressure2112 May. 12 at 2:25 PM

$BIAF down she goes...

0 · Reply

TMacIE May. 12 at 2:18 PM

$BIAF

0 · Reply

Emiclea May. 12 at 1:28 PM

$BIAF let’s go !! Run it !!

0 · Reply

Stock_Catcher May. 12 at 1:15 PM

$BIAF bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

1 · Reply

focafoca99 May. 8 at 12:48 PM

$BIAF released its Q1 2026 financial results via a press release attached to its 8‑K.

0 · Reply

PyroMatic May. 5 at 4:21 AM

1 · Reply

BiotechGoldenEra May. 5 at 2:27 AM

$BIAF bottom?

0 · Reply

InvestingSpaceman May. 4 at 10:10 PM

$SATL $BMNR $BIAF $ACHR OD

0 · Reply

InvestingSpaceman May. 4 at 8:09 PM

$BMNR $BIAF DP

0 · Reply

MicrocapCowboy May. 1 at 3:41 PM

$BIAF I made a killing on this…..120% return getting in and out in 9 days. I think we can expect another move eventually but clearly, this new dilution needs to run its course. I think the time back in is around $1.25…..yes I think it will go that low before it bounces back….and could even come with another reverse split. Despite the cash flow issue, the company is poised for near term success with the recent changes in product strategy.

1 · Reply

focafoca99 Apr. 30 at 8:58 PM

$BIAF bioAffinity stockholders approved a large increase in shares reserved under the 2024 equity incentive plan at the annual meeting.

0 · Reply

brallt Apr. 30 at 7:42 PM

$BIAF sleeper low volume micro float daily breakout forming at DRMA. do not forget to get your starter before the 1.40 breakout.

0 · Reply

stocksbuytrade Apr. 30 at 2:32 PM

$WNW long halt👀👀👀. $CANF $BIAF $AKAN

0 · Reply

321rip Apr. 30 at 7:30 AM

$BIAF looks like yest. p/b s/o last of weak sistas, O.N. +9% 1/2 hr prior to pre mkt

0 · Reply

TooMuchSeaWater Apr. 29 at 2:24 AM

$BIAF it was bear last month wtf

0 · Reply

321rip Apr. 28 at 11:37 PM

$BIAF forming a bull pennant off today's HI

0 · Reply

topstockalerts Apr. 28 at 8:00 PM

$BIAF kinda surprised how strong this is today

0 · Reply

NorthernMonkey1 Apr. 28 at 7:43 PM

AH Hold list 😎 🚨 ⚠️ $CXAI $ROLR $PAPL $BIAF Good luck peeps ✌️ 😎

0 · Reply

Market Cap	8.86M
Revenue (ttm)	6.16M
Net Income (ttm)	-14.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-242.05%
Debt to Equity Ratio	0.02

Volume	672,200
Avg Vol	10,807,008
Day's Range	N/A - N/A
Shares Out	4.50M
Stochastic %K	9%
Beta	-1.19
Analysts	Strong Buy
Price Target	$6.00